Diabetes mellitus, hyperglycaemia and cancer

Fuller, 1983, Diabetes mortality: new light on an underestimated public health problem, Diabetologia, 24, 336, 10.1007/BF00251820

Green, 1984, Epidemiological studies of diabetes mellitus in Denmark. 5. Mortality and causes of death among insulin-treated diabetic patients, Diabetologia, 20, 468

Steenland, 1995, Cancer incidence in the National Health and Nutrition Survey I. Follow-up data: diabetes, cholesterol, pulse, and physical activity, Cancer Epidemiol Biomarkers Prevention, 4, 807

Shoff, 1998, Diabetes, body size, and risk of endometrial cancer, Am J Epidemiol, 148, 234, 10.1093/oxfordjournals.aje.a009630

Calle, 2003, Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults, N Engl J Med, 348, 1625, 10.1056/NEJMoa021423

Huxley, 2005, Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies, Br J Cancer, 92, 2076, 10.1038/sj.bjc.6602619

Hemkens, 2009, Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study, Diabetologia, 52, 1732, 10.1007/s00125-009-1418-4

Jonasson, 2009, Insulin glargine use and short-term incidence of malignancies–a population-based follow-up study in Sweden, Diabetologia, 52, 1745, 10.1007/s00125-009-1444-2

Colhoun, 2009, Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group, Diabetologia, 52, 1755, 10.1007/s00125-009-1453-1

Currie, 2009, The influence of glucose-lowering therapies on cancer risk in type 2 diabetes, Diabetologia, 52, 1766, 10.1007/s00125-009-1440-6

Green, 1985, Frequency of cancer among insulin-treated diabetic patients in Denmark, Diabetologia, 28, 128, 10.1007/BF00273858

Zendehdel, 2003, Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden, J Nat Cancer Inst, 23, 1797, 10.1093/jnci/djg105

Inoue, 2006, Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan, Arch Int Med, 166, 1871, 10.1001/archinte.166.17.1871

Tseng, 2009, Secular trend for mortality from breast cancer and the association between diabetes and breast cancer in Taiwan between 1995 and 2006, Diabetologia, 52, 240, 10.1007/s00125-008-1204-8

Larsson, 2007, Diabetes mellitus and risk of breast cancer: a meta-analysis, Int J Cancer, 121, 856, 10.1002/ijc.22717

Stattin, 2007, Prospective study of hyperglycemia and cancer risk, Diabetes Care, 30, 561, 10.2337/dc06-0922

Jee, 2005, Fasting serum glucose level and cancer risk in Korean men and women, JAMA, 293, 194, 10.1001/jama.293.2.194

Rapp, 2006, Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria, Diabetologia, 49, 945, 10.1007/s00125-006-0207-6

Bonovas, 2004, Diabetes mellitus and risk of prostate cancer: a meta-analysis, Diabetologia, 47, 1071, 10.1007/s00125-004-1415-6

Kasper, 2006, A meta-analysis of diabetes mellitus and the risk of prostate cancer, Cancer Epidemiol Biomarkers Prev, 15, 2056, 10.1158/1055-9965.EPI-06-0410

Khaw, 2004, Preliminary communication: glycated haemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European Prospective Investigation into Cancer-Norfolk Study, Cancer Epidemiol Biomarkers Prev, 13, 915, 10.1158/1055-9965.915.13.6

Doll, 1992, The lessons of life: keynote address to the nutrition and cancer conference, Cancer Res, 52, 2024S

International Agency for Research on Cancer: IARC handbooks of cancer prevention. Vol.8: Fruit and vegetables. Lyon, France 2003.

Pan, 1997, Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and diabetes study, Diabetes Care, 20, 537, 10.2337/diacare.20.4.537

Tuomilehto, 2001, Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance, N Engl J Med, 344, 1343, 10.1056/NEJM200105033441801

Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403.

Friedenreich, 2001, Physical activity and cancer prevention: from observational to intervention research, Cancer Epidemiol Biomarkers Prev, 10, 287

Khandwala, 2000, The effects of insulin-like growth factors on tumorigenesis and neoplastic growth, Endocr Rev, 21, 215, 10.1210/er.21.3.215

Wolf, 2005, Diabetes mellitus and breast cancer, Lancet Oncol, 6, 103, 10.1016/S1470-2045(05)01736-5

Le Roith, 1997, Seminars in medicine on the Beth Israel Deaconess Medical Center: insulin-like growth factors, N Engl J Med, 336, 633, 10.1056/NEJM199702273360907

Balkau, 2001, Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites. The Paris Prospective Study, Diabetes Care, 24, 843, 10.2337/diacare.24.5.843

Maison, 1998, Growth hormone, a risk factor for premature mortality in healthy subjects. Data from the Paris Prospective Study, BMJ, 316, 1132, 10.1136/bmj.316.7138.1132

Major, 2010, Insulin-like growth factor-1 and cancer mortality in older men, J Clin Endocrinol Metab, 95, 1054, 10.1210/jc.2009-1378

Goodman-Gruen, 2000, Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women, Diabetes Care, 23, 912, 10.2337/diacare.23.7.912

Gann, 1996, Prospective study of sex hormone levels and risk of prostate cancer, J Natl Cancer Inst, 88, 1118, 10.1093/jnci/88.16.1118

Frayling, 2008, A genetic link between type 2 diabetes and prostate cancer, Diabetologia, 51, 1757, 10.1007/s00125-008-1114-9

Bowker, 2006, Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin, Diabetes Care, 29, 254, 10.2337/diacare.29.02.06.dc05-1558

Hawley, 2003, Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade, J Biol, 2, 28, 10.1186/1475-4924-2-28

Lizcano, 2004, LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1, EMBO J, 23, 833, 10.1038/sj.emboj.7600110

Evans, 2005, Metformine and reduced risk of cancer in diabetic patients, Br Med J, 330, 1304, 10.1136/bmj.38415.708634.F7

Libby, 2009, New users of metformine are at low risk of incident cancer, Diabetes Care, 32, 1620, 10.2337/dc08-2175

Landman, 2010, Metformin associated with lower cancer mortality in type 2 diabetes, Diabetes Care, 33, 322, 10.2337/dc09-1380

Yang, 2004, Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients, Gastroenterology, 127, 1044, 10.1053/j.gastro.2004.07.011

Dormandy, 2005, Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial, Lancet, 366, 1279, 10.1016/S0140-6736(05)67528-9

Govindarajan, 2007, Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes, J Clin Oncol, 12, 1476, 10.1200/JCO.2006.07.2777

Monami, 2008, Rosiglitazone and risk of cancer. A meta-analysis of randomized clinical trials, Diabetes Care, 31, 1455, 10.2337/dc07-2308

Kahn, 2006, Glycemic durability of rosiglitazone, metformine or glyburide monotherapy, N Engl J Med, 355, 2427, 10.1056/NEJMoa066224

Murtola, 2008, Antidiabetic medication and prostate cancer risk: a population-based case-control study, Am J Epidemiol, 168, 925, 10.1093/aje/kwn190

Simon, 1992, The influence of aging on plasma sex hormones in men: the Telecom Study, Am J Epidemiol, 135, 783, 10.1093/oxfordjournals.aje.a116365

Kurtzhals, 2000, Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use, Diabetes, 49, 999, 10.2337/diabetes.49.6.999

Pocock, 2009, Insulin glargin and malignancy: an unwarranted alarm, Lancet, 374, 511, 10.1016/S0140-6736(09)61307-6

Garg, 2009, Insulin glargine and cancer–An ubsubstantiated allegation, Diabetes Techn Ther, 11, 473, 10.1089/dia.2009.1705

Nagel, 2010, Insulin resistance and increased risk for malignant neoplasms: confounding the data on insulin glargine, Diabetologia, 53, 206, 10.1007/s00125-009-1535-0

Simon, 2010, Diabetes treatment with insulin glargine and risk of malignancy: methodological pitfalls and ethical issues, Diabetologia, 53, 204, 10.1007/s00125-009-1572-8

Grouven, 2010, Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues, Diabetologia, 53, 209, 10.1007/s00125-009-1582-6

Yki-Järvinen, 2006, Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study, Diabetologia, 49, 442, 10.1007/s00125-005-0132-0

Pan, 2007, Insulin glargine vs NPH insulin therapy in Asian type 2 diabetes patients, Diabetes Res Clin Pract, 76, 111, 10.1016/j.diabres.2006.08.012

Riddle, 2003, The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients, Diabetes Care, 26, 3080, 10.2337/diacare.26.11.3080

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–53.

Bender, 2001, Adjusting for multiple testing-when and how?, J Clin Epidemiol, 54, 343, 10.1016/S0895-4356(00)00314-0

Smith, 2009, Does diabetes therapy influence the risk of cancer?, Diabetologia, 52, 1699, 10.1007/s00125-009-1441-5

Romon, 2009, Description de la mortalité et des causes de décès dans une cohorte d’adultes diabétiques, en France métropolitaine–ENTRED 2001, Bull Epidemiol Hebd, 42–43, 469

Eyre, 2004, Preventing cancer, cardiovascular disease, and diabetes–A common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association, Diabetes Care, 27, 1812, 10.2337/diacare.27.7.1812

Hercberg, 2008, The French National Nutrition and Health Program: 2001–2006–2010, Int J Public Health, 53, 68, 10.1007/s00038-008-7016-2